[THE INVESTOR] Dong-A ST’s prescription drugs will turn around and it will continue to grow overseas, said Hanwha Investment and Securities on Nov. 16, maintaining a “buy” recommendation and raising the target price to 130,000 won (US$117.52) from 100,000 won.
The effect of its blockbuster gastrointestinal therapy Stillen’s price markdown will come to an end and revenue from prescription drugs will turn around. Sales of its major products, including indigestion drug and allergic rhinitis treatment, will also stabilize, said analyst Shin Hyeon-jun.
Its pipeline will be reevaluated too, according to the securities firm, as a series of drug candidates proceed to the next phase of clinical trials in the US.
Revenue and profits from overseas markets will contribute more as exports of growth hormone therapy and energy drink Bacchus continues to grow steadily, said the analyst, adding that there is no need to discount its stocks any more.
By Hwang You-mee (firstname.lastname@example.org)